Skip to main content
. 2022 Jun 1;93(8):849–857. doi: 10.1136/jnnp-2021-328568

Table 2.

The association of overall mean sNfL level with MRI atrophy and clinical measures at the 10-year follow-up, with a random intercept for study site, corrected for age, sex, DMT use, eTIV, BL T2LC, BL Gd+ LC and fGd+

MRI/clinical measurement N B Std. B 95% CI P value* Marginal R2 Conditional R2
Total GM volume 65 −471.6 −0.147 −1236.446 to 293.239 0.514 0.385 0.607
Total WM volume 65 −110.9 −0.030 −945.240 to 723.354 0.920 0.380 0.380
Total deep GM volume 65 −78.12 −0.221 −162.299 to 6.054 0.429 0.423 0.513
Thalamus volume 65 −12.778 −0.203 −29.365 to 3.808 0.487 0.276 0.501
Mean Cth 65 −0.002 −0.255 −0.004 to 1.069×10−4 0.782 0.308 0.584
logLesion volume† 68 −2.830×10−4 −0.001 −0.006 to 0.006 0.989 0.351 0.499
Lesion count 68 0.112 0.086 −0.046 to 0.270 0.488 0.272 0.430
EDSS≥4‡ 77 0.000 1.000 0.952 to 1.052 0.985
logT25FW† 72 −0.001 −0.158 −0.004 to 0.001 0.470 0.096 0.373
logChange in T25FW† 70 −0.001 −0.129 −0.003 to 3.932×10−4 0.581 0.062 0.258
logD9-HPT† 71 0.002 0.263 −4.058×10−6 to 0.004 1.000 0.309 0.348
logChange in D9-HPT† 69 −0.001 −0.076 −0.005 to 0.003 0.735 0.195 0.229
logND9-HPT† 70 −0.001 −0.073 −0.002 to 0.001 0.670 0.278 0.368
logChange in ND9-HPT† 68 −0.004 −0.234 −0.009 to 3.350×10−4 0.550 0.170 0.239
PASAT 72 0.088 0.112 −0.085 to 0.260 0.550 0.189 0.247
Change in PASAT 70 0.038 0.063 −0.082 to 0.157 0.738 0.143 0.431
Oral SDMT 67 0.110 0.128 −0.094 to 0.314 0.563 0.222 0.434

Marginal R2: variance explained by fixed effects.

Conditional R2: variance explained by both fixed and random effects.

*Adjusted p values after controlling the false discovery rate (FDR) for multiple hypothesis testing.

†Dependent variable log transformed due to non-normality (log-linear transformation).

‡Analysed by logistic regression, regression coefficient (B), odds ratio (Std. B) and 95% CI of odds ratio reported.

B, beta; BL, baseline; Cth, cortical thickness; D9-HPT, dominant hand Nine-Hole Peg Test; DMT, disease modifying therapy; EDSS, Expanded Disability Status Scale; eTIV, estimated total intracranial volume; fGd+, fraction of MRI scans with new Gadolinium-enhancing lesion; Gd+, gadolinium-enhancing; GM, grey matter; LC, lesion count; ND9-HPT, non-dominant hand Nine-Hole Peg Test; PASAT, Paced Auditory Serial Addition Test; SDMT, Symbol Digit Modalities Test; sNfL, serum neurofilament light chain; Std, standardised; T25FW, timed 25-foot walk; WM, white matter.